Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

4.775 +0.085 (+1.81%)
Streaming Delayed Price Updated: 9:30 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Leadership Succession
From Phathom Pharmaceuticals
Via GlobeNewswire
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive... 
From Phathom Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.